Cardiovascular Drugs and Therapy最新文献

筛选
英文 中文
Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data. 替西帕肽优于西马鲁肽的脑血管预后:对观察数据谨慎解释的呼吁。
IF 3.1 3区 医学
Cardiovascular Drugs and Therapy Pub Date : 2025-10-11 DOI: 10.1007/s10557-025-07789-9
Artur Dziewierz, Zbigniew Siudak
{"title":"Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data.","authors":"Artur Dziewierz, Zbigniew Siudak","doi":"10.1007/s10557-025-07789-9","DOIUrl":"https://doi.org/10.1007/s10557-025-07789-9","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145273857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship Between the Incidence of Metabolic Syndrome and Breast Cancer. 代谢综合征发病率与乳腺癌的关系
IF 3.1 3区 医学
Cardiovascular Drugs and Therapy Pub Date : 2025-10-07 DOI: 10.1007/s10557-025-07780-4
Naoki Kimoto, Yohei Miyashita, Yutaka Yata, Takeshi Aketa, Masami Yabumoto, Yasushi Sakata, Takashi Washio, Seiji Takashima, Masafumi Kitakaze
{"title":"Relationship Between the Incidence of Metabolic Syndrome and Breast Cancer.","authors":"Naoki Kimoto, Yohei Miyashita, Yutaka Yata, Takeshi Aketa, Masami Yabumoto, Yasushi Sakata, Takashi Washio, Seiji Takashima, Masafumi Kitakaze","doi":"10.1007/s10557-025-07780-4","DOIUrl":"https://doi.org/10.1007/s10557-025-07780-4","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer affects females from puberty onward, with incidence rates increasing with age. Although metabolic syndrome (MetS) has reportedly increased the incidence of almost all cancers, no clear consensus on the role of MetS in breast cancer development exists. We aimed to clarify the effects of MetS on breast cancer incidence.</p><p><strong>Methods: </strong>To investigate this relationship, we analyzed Japanese healthcare data of females from 2005 to 2020 and examined the incidence of breast cancer. MetS was evaluated based on the Japanese criteria or the NCEP ATP III guidelines at enrollment. Of 1,144,791 participants without missing data in our general public cohort, 32,775 with breast cancer at the beginning of the observation period were excluded; 54,330 participants with breast cancer were identified during the observation period.</p><p><strong>Results: </strong>Both pre-stage MetS and MetS, defined using the Japanese criteria, were associated with the less frequent incidence of breast cancer (hazard ratios [HRs], 0.90; 95% CI, 0.86-0.94; p < 0.005: HR, 0.83; 95% CI, 0.80-0.87; p < 0.005). Furthermore, MetS using NCEP ATP III was associated with the lower HR (0.87: CI, 0.84-0.90; p < 0.005), and the number of the factors from 1 to 5 was gradually associated with the lower HRs. Analysis according to age group revealed that this observation was the most prominent in the < 50-year-old group.</p><p><strong>Conclusion: </strong>MetS is associated with the less frequent breast cancer incidence in females, especially aged < 50 years.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of the Pentose Phosphate Pathway in Cardiovascular Diseases. 戊糖磷酸途径在心血管疾病中的作用。
IF 3.1 3区 医学
Cardiovascular Drugs and Therapy Pub Date : 2025-10-04 DOI: 10.1007/s10557-025-07788-w
Zeyu Chen, Ying Zhang, Cheng Qian, Lin Xia
{"title":"The Role of the Pentose Phosphate Pathway in Cardiovascular Diseases.","authors":"Zeyu Chen, Ying Zhang, Cheng Qian, Lin Xia","doi":"10.1007/s10557-025-07788-w","DOIUrl":"https://doi.org/10.1007/s10557-025-07788-w","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) are the leading contributors to global mortality, characterized by multifactorial etiology involving diverse cell types such as cardiomyocytes and immune cells. Metabolic reprogramming in cardiomyocytes and immune cells is involved in the pathophysiology of CVDs, and the pentose phosphate pathway (PPP) plays a critical role. The PPP mainly generates nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate (R5P). NADPH not only maintains cellular antioxidant capacity by regenerating reduced glutathione (GSH) and thioredoxin (Trx) but also participates in reactive oxygen species (ROS) production through NADPH oxidases (NOX) under specific conditions, thus exerting dual roles in cardioprotection and oxidative damage. Meanwhile, R5P contributes to nucleotide biosynthesis, supporting cell cycle progression and immune cell expansion. Therefore, PPP is necessary for cellular proliferation and function. In cardiomyocytes, enhanced PPP reduces oxidative stress and facilitates myocardial repair. The PPP modulates phenotypes and functions in immune cells and is involved in inflammatory responses and tissue repair. Therapeutic interventions targeting key enzymes of the PPP, like glucose-6-phosphate dehydrogenase (G6PDH), can alleviate oxidative damage, reduce pathological fibrosis, and modulate immune cell activity in CVDs. Some inhibitors of G6PDH, such as dehydroepiandrosterone and 6-amino-nicotinamide (6-AN), are in the preclinical stage. This review emphasizes the importance of the PPP in CVDs, advocating for targeted metabolic therapies to enhance treatment efficacy and patient outcomes in CVDs.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autophagy and Antifibrotic Effects of Crocetin After Myocardial Infarction. 西红花素在心肌梗死后的自噬和抗纤维化作用。
IF 3.1 3区 医学
Cardiovascular Drugs and Therapy Pub Date : 2025-09-30 DOI: 10.1007/s10557-025-07787-x
Xinyu Nie, Xingyue Feng, Can Xu
{"title":"Autophagy and Antifibrotic Effects of Crocetin After Myocardial Infarction.","authors":"Xinyu Nie, Xingyue Feng, Can Xu","doi":"10.1007/s10557-025-07787-x","DOIUrl":"https://doi.org/10.1007/s10557-025-07787-x","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Angiography-Derived Physiology in Non-culprit Vessels: Translational Barriers from Infarct Stratification to Pharmacotherapy Adjustment. 非罪魁祸首血管的血管造影衍生生理学:从梗死分层到药物治疗调整的转化障碍。
IF 3.1 3区 医学
Cardiovascular Drugs and Therapy Pub Date : 2025-09-30 DOI: 10.1007/s10557-025-07786-y
Noor-Ul-Eman Haider, Uzair Ali Khan, Talha Imran
{"title":"Angiography-Derived Physiology in Non-culprit Vessels: Translational Barriers from Infarct Stratification to Pharmacotherapy Adjustment.","authors":"Noor-Ul-Eman Haider, Uzair Ali Khan, Talha Imran","doi":"10.1007/s10557-025-07786-y","DOIUrl":"https://doi.org/10.1007/s10557-025-07786-y","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145197765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on: "Effect of Bisoprolol Versus Other Beta-Blockers on Glycemic Control and Metabolic Parameters in Type 2 Diabetes: A Retrospective Cohort Study". 评论:“比索洛尔与其他β受体阻滞剂对2型糖尿病血糖控制和代谢参数的影响:一项回顾性队列研究”。
IF 3.1 3区 医学
Cardiovascular Drugs and Therapy Pub Date : 2025-09-24 DOI: 10.1007/s10557-025-07782-2
Xiao-Tian Wang, Pingxiaoke Qin
{"title":"Comment on: \"Effect of Bisoprolol Versus Other Beta-Blockers on Glycemic Control and Metabolic Parameters in Type 2 Diabetes: A Retrospective Cohort Study\".","authors":"Xiao-Tian Wang, Pingxiaoke Qin","doi":"10.1007/s10557-025-07782-2","DOIUrl":"https://doi.org/10.1007/s10557-025-07782-2","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study. 冠状动脉扩张患者急性冠状动脉综合征后抗凝与抗血小板治疗:一项回顾性队列研究。
IF 3.1 3区 医学
Cardiovascular Drugs and Therapy Pub Date : 2025-09-24 DOI: 10.1007/s10557-025-07784-0
Fabio Solis-Jiménez, Ximena Latapi-Ruiz Esparza, Hannah Priscila Guzman-Solorzano, Monserrat Villalobos-Pedroza, Luis Angel Morales-Villamil, Braiana Angeles Diaz-Herrera, Sarai Hernandez-Pastrana, Rodrigo Gopar-Nieto, Eduardo A Arias-Sanchez, Luis Alfonso Marroquín-Donday, Gian Manuel Jiménez-Rodríguez, Daniel Sierra-Lara, Diego Araiza-Garaygordobil, Alexandra Arias-Mendoza
{"title":"Anticoagulant versus Antiplatelet Therapy After Acute Coronary Syndromes in Patients with Coronary Artery Ectasia: A Retrospective Cohort Study.","authors":"Fabio Solis-Jiménez, Ximena Latapi-Ruiz Esparza, Hannah Priscila Guzman-Solorzano, Monserrat Villalobos-Pedroza, Luis Angel Morales-Villamil, Braiana Angeles Diaz-Herrera, Sarai Hernandez-Pastrana, Rodrigo Gopar-Nieto, Eduardo A Arias-Sanchez, Luis Alfonso Marroquín-Donday, Gian Manuel Jiménez-Rodríguez, Daniel Sierra-Lara, Diego Araiza-Garaygordobil, Alexandra Arias-Mendoza","doi":"10.1007/s10557-025-07784-0","DOIUrl":"https://doi.org/10.1007/s10557-025-07784-0","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with coronary ectasia (CAE) have an increased risk of major cardiovascular events (MACE). Current preventive treatments are uncertain, with oral anticoagulants often prescribed based on limited retrospective studies. Our aim is to help address the question: what is the most appropriate treatment?</p><p><strong>Methods: </strong>Using a retrospective cohort of patients with an ACS and CAE in a single center in Mexico City, two groups were observed based on the treatment at discharge: dual antiplatelet therapy (group 1) and anticoagulation with either a VKA or a DOAC, regardless of antiplatelet therapy (group 2). The main outcome was MACE, which was a composite of all-cause mortality, reinfarction, and ischemic stroke at 4.5 years follow-up.</p><p><strong>Results: </strong>A total of 354 patients admitted for ACS and CAE were included. 228 (64.4%) patients were classified in the DAPT group and 126 (35.5%) in the anticoagulants group. The DAPT group had higher type 2 diabetes rates, NSTEMI presentation, and lower-grade ectasia. The anticoagulation group had higher STEMI presentation and higher-grade ectasia. The DAPT group had 33 (14.5%) events of MACE, whereas the anticoagulation group had 16 (13.1%) events. Anticoagulants were not associated with a risk reduction of the primary endpoint (HR 0.95; 95% CI, 0.47-1.54; p = 0.59), nor any of the individual components.</p><p><strong>Conclusion: </strong>This retrospective cohort study showed similar effectiveness between DAPT and anticoagulation in patients with ACS and CAE for preventing MACE, and lower bleeding risk. Further research is needed to identify optimal candidates for each antithrombotic regime.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145129990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Underuse of SGLT2 Inhibitors in Ambulatory Heart Failure Care: A Call to Action. SGLT2抑制剂在动态心衰护理中的使用不足:呼吁采取行动
IF 3.1 3区 医学
Cardiovascular Drugs and Therapy Pub Date : 2025-09-19 DOI: 10.1007/s10557-025-07783-1
Sana Ullah, Umaid Khan
{"title":"Underuse of SGLT2 Inhibitors in Ambulatory Heart Failure Care: A Call to Action.","authors":"Sana Ullah, Umaid Khan","doi":"10.1007/s10557-025-07783-1","DOIUrl":"https://doi.org/10.1007/s10557-025-07783-1","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statin-Related Transaminitis-Is It Necessary to Stop Statins? 他汀类药物相关的转氨性感染——有必要停用他汀类药物吗?
IF 3.1 3区 医学
Cardiovascular Drugs and Therapy Pub Date : 2025-09-19 DOI: 10.1007/s10557-025-07771-5
Brian Tomlinson, Weiwei Zeng
{"title":"Statin-Related Transaminitis-Is It Necessary to Stop Statins?","authors":"Brian Tomlinson, Weiwei Zeng","doi":"10.1007/s10557-025-07771-5","DOIUrl":"https://doi.org/10.1007/s10557-025-07771-5","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bempedoic Acid and the Uric Acid Paradox: Reflections on the Recent Meta-analysis. 苯足酸与尿酸悖论:对近期meta分析的反思。
IF 3.1 3区 医学
Cardiovascular Drugs and Therapy Pub Date : 2025-09-18 DOI: 10.1007/s10557-025-07781-3
Luca Bonanni, Nicola Ferri
{"title":"Bempedoic Acid and the Uric Acid Paradox: Reflections on the Recent Meta-analysis.","authors":"Luca Bonanni, Nicola Ferri","doi":"10.1007/s10557-025-07781-3","DOIUrl":"https://doi.org/10.1007/s10557-025-07781-3","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信